pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›XENON, XE-133
drug
save

XENON, XE-133

updated 3mo ago
by CURIUM
community read0 votes

all catalysts(0)

nothing on the calendar yet

Trials studying XENON, XE-133

  • N/APulmonary Assessment in Thoracic Insufficiency Syndrome Patientswithdrawn
  • phase2Xenon MRI and Progressive ILDactive not recruitingn=60
  • phase2Lung Functional Avoidance Radiotherapy Using Hyperpolarized Xenon MRInot yet recruitingn=10
  • phase1Functional Lung Avoidance Radiation Therapy Using Hyperpolarized Xenon-129 MRIterminatedn=9
  • —Hyperpolarized Xenon Functional Lung Imaging in COPD Patients Undergoing Targeted Lung Denervationwithdrawn
  • —Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthmarecruitingn=5
  • phase1Functional and Structural Assessment of Endobronchial Valve Recipients Using Dynamic Hyperpolarized Xenon-129 MRIterminatedn=27
  • —Assessment of Chronic Lung Allograft Dysfunction Using Single-breath & Multi-breath Hyperpolarized Xenon-129 MRIterminatedn=45
more trials →

News(2)

  • NewLimit’s $435M megaround; Lilly’s busy dealmaking week
    The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
    biopharma_dive · 2mo ago
  • A year after Vertex’s big launch, pain drug research faces a pivotal moment
    Journavx revived an area of development long considered a graveyard. Can any other pain drugs keep investor excitement going?
    biopharma_dive · 2mo ago
brand
XENON, XE-133
generic
XENON
Data sources
ClinicalTrials.gov
last refreshed 1h ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?